home / stock / pvct / pvct news

PVCT News and Press, Provectus Biopharmaceuticals Inc From 05/03/22

Stock Information
Company Name: Provectus Biopharmaceuticals Inc
Stock Symbol: PVCT
Market: OTC
Website: provectusbio.com
Menu
PVCT PVCT Quote PVCT Short PVCT News PVCT Articles PVCT Message Board
Get PVCT Alerts

News, Short Squeeze, Breakout and More Instantly...
PVCT - Provectus Biopharmaceuticals Announces Notice of Allowance of First U.S. Patent of PH-10 Immuno-Dermatology Agent for Treatment of Inflammatory Dermatoses and Epithelial Diseases

KNOXVILLE, TN, May 03, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the United States Patent and Trademark Office (USPTO) has allowed US patent (USP) application 16/204,832, “ Combination of local and systemic therapies for enhanced treatment of dermatologi...
PVCT - Provectus Biopharmaceuticals Announces Acceptance of PV-10® Immunotherapy Abstract for Metastatic Uveal Melanoma at American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

KNOXVILLE, TN, April 27, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of investigational cancer immunotherapy PV-10, a formulation of Provectus’ immunogenic-small molecule and pharmaceutical-grade rose bengal sodium (RBS), ...

PVCT - Provectus to get US patent for PV-10 to treat hematologic diseases

Provectus (OTC:PVCT) said the U.S. Patent and Trademark Office (USPTO) allowed a patent application covering the use of PV-10 to treat hematologic diseases. The company said the U.S. patent application 16/688,319 is titled 'Composition and Method for Treating Hematologic Cancers.' The co...

PVCT - Provectus Biopharmaceuticals Announces Notice of Allowance of First U.S. Patent Application for Use of PV-10® Immunotherapy in Hematology

KNOXVILLE, TN, April 26, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the United States Patent and Trademark Office (USPTO) has allowed US patent application 16/688,319, “ Composition and Method for Treating Hematologic Cancers ,” covering the use ...
PVCT - Provectus Biopharmaceuticals Seeks Stockholder Approval at 2022 Annual Meeting for Authority to Undertake Reverse Split of Outstanding Equities and Reduce Number of Authorized Equities by Same Ratio

KNOXVILLE, TN, April 19, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that, in conjunction with the filing of the Company’s preliminary 2022 proxy statement (Pre-14A), Provectus’ Board of Directors (Board) seeks approvals at the Company’s 2022 Annual...

PVCT - Provectus Biopharmaceuticals Names Aru Narendran, MD, PhD to Scientific Advisory Board

KNOXVILLE, TN, April 14, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced the addition of Aru Narendran, MD, PhD to the Company’s Scientific Advisory Board. Dr. Narendran is a professor in the departments of Pediatrics, Oncology, and Biochemistry & Molecular Biolo...

PVCT - Provectus Biopharmaceuticals Announces Presentation of Multiple Protein Kinase Signaling Targets, including WNK1, for PV-10® Immunotherapy at American Association for Cancer Research (AACR) 2022 Annual Meeting

KNOXVILLE, TN, April 11, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that preclinical research on systemic administration of investigational cancer immunotherapy PV-10 (rose bengal sodium) for the treatment of high-risk and refractory adult solid tumor cancers is being ...
PVCT - Provectus reports synthesis of new halogenated xanthene small molecule

Provectus (OTC:PVCT) said it has developed and manufactured a second halogenated xanthene (HX), adding to its lead, clinical-stage, HX small molecule called rose bengal sodium (RBS). The company said its intellectual property comprises an entire class of related HX molecules that ar...

PVCT - Provectus Biopharmaceuticals Announces Synthesis of New Halogenated Xanthene Small Molecule

KNOXVILLE, TN, March 24, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company has successfully developed and manufactured a second halogenated xanthene (HX), adding to its lead, clinical-stage, HX small molecule called rose bengal sodium (RBS). The molecul...

PVCT - Provectus Biopharmaceuticals Announces Oral Presentation of Updated Study Data from Metastatic Neuroendocrine Cancer Phase 1 Trial of PV-10® at 2022 European Neuroendocrine Tumor Society (ENETS) Annual Conference

KNOXVILLE, TN, March 16, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of investigational cancer immunotherapy PV-10 (rose bengal sodium) for the treatment of neuroendocrine tumors (NET) metastatic to the liver (mNET) refractory to...
Previous 10 Next 10